ARS Pharmaceuticals, Inc. — Director's Dealing 2022

Dec 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2022-11-29

Reporting Person: Scott Kathleen D. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-29	Common Stock	P	8250	$6.2432	Acquired	8250	Indirect

Footnotes

F1: The price reported in Column 4 is the weighted average price. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.26, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2: By Scott 2008 Trust Dated 3/28/08.